Reneo Pharmaceuticals, Inc.

NASDAQ:RPHM

18.2 (USD) • At close October 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202420232022202120202019
Revenue 000000
Cost of Revenue 000.5290.050.0370.034
Gross Profit 0-0.525-0.529-0.05-0.037-0.034
Gross Profit Ratio 000000
Reseach & Development Expenses 43.79556.08837.70528.16915.94413.097
General & Administrative Expenses 10.59125.7916.14311.6493.6082.376
Selling & Marketing Expenses 000000
SG&A 10.59125.7916.14311.6493.6082.376
Other Expenses 00.651.8930.0480.0873.037
Operating Expenses 54.38683.05353.84839.81819.55215.473
Operating Income -54.386-83.053-53.848-39.818-19.552-15.473
Operating Income Ratio 000000
Total Other Income Expenses Net 05.6651.8930.0480.0873.037
Income Before Tax 0-77.388-51.955-39.77-19.465-12.436
Income Before Tax Ratio 000000
Income Tax Expense 00-1.893-0.187-0.169-0.138
Net Income 0-77.388-50.062-39.77-19.465-12.436
Net Income Ratio 000000
EPS 0-2.3-2.04-2.19-0.8-1.6
EPS Diluted 0-2.3-2.04-2.19-0.8-1.6
EBITDA -54.386-82.233-53.76-39.768-19.515-15.439
EBITDA Ratio 000000